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ScienceDirectApathy and impulsivity are common and often coexistent
consequences of frontotemporal lobar degeneration (FTLD).
They increase patient morbidity and carer distress, but remain
under-estimated and poorly treated. Recent trans-diagnostic
approaches that span the spectrum of clinical presentations of
FTLD and parkinsonism, indicate that apathy and impulsivity
can be fractionated into multiple neuroanatomical and
pharmacological systems. These include ventral/dorsal
frontostriatal circuits for reward-sensitivity, response-
inhibition, and decision-making; moderated by noradrenaline,
dopamine, and serotonin. Improved assessment tools, formal
models of cognition and behavior, combined with brain imaging
and psychopharmacology, are creating new therapeutic
targets and establishing principles for stratification in future
clinical trials.
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Introduction
Apathy and impulsivity are two problems that coexist
in frontotemporal lobar degeneration (FTLD) syn-
dromes, including the behavioral variant of frontotem-
poral dementia (bvFTD), primary progressive aphasia,
progressive supranuclear palsy (PSP), and corticobasal
syndrome [1,2,3,4]. Epidemiological data indicate that
apathy and impulsivity are common in FTLD syndromes
[5], and cause significant patient morbidity and carer
distress. Despite progress in understanding apathy andCurrent Opinion in Behavioral Sciences 2018, 22:14–20 impulsivity in other diseases [6], there is a limited
evidence base for clinical management in FTLD
syndromes.
Apathy and impulsivity have been conceived as belong-
ing to opposite ends of a behavioral spectrum of dopa-
mine-dependent abnormal motivation [7]. Although rel-
evant to some aspects of apathy and impulsivity in certain
neuropsychiatric disorders, this approach cannot explain
their frequent co-occurrence in FTLD, or the fact that
FTLD patients with more apathy also manifest more
impulsivity (Figure 1) [8]. As a concrete illustration of
their co-existence, we commonly observe apathetic
patients (e.g. sitting in a chair for hours) whose first action
in the day is an uncontrolled and impulsive movement
that put them at risk of falling and reporting injuries. This
‘alliance’ of apathy and impulsivity is also acknowledged
in the clinical diagnostic criteria for bvFTD [4] and
PSP [3].
We propose that apathy and impulsivity are behavioral
constructs with multiple components, and that these
components are positively correlated due to common-
alities in neuroanatomical and pharmacological conse-
quences of pathology, leading to dysregulation of deci-
sion-making, response-inhibition, and motivation.
Alternatively, apathy and impulsivity may originate
from separate brain structures and pharmacological
mechanisms which are difficult to fractionate empirically
due to the widespread nature of the FTLD-related
pathological changes. However, the co-existence of apa-
thy and impulsivity in other, non-degenerative, condi-
tions (e.g. drug addiction) suggests that this latter hypoth-
esis is less likely [9,10].
In parallel with correlative investigations of the neuroan-
atomical substrates of apathy and impulsivity, we present
a computational approach embedded in the decision
theory to describe and characterize the co-existence of
apathy and impulsivity in FTLD syndromes in terms of
latent neurocognitive mechanisms [11,12].
Finally, we highlight the role played by neurotransmitters
other than dopamine, in part because apathy and impul-
sivity in FTLD are clinically unresponsive to standard
dopaminergic therapies and in part because of emerging
evidence of serotonergic and noradrenergic contributions
to both apathy and impulsivity [13–16].www.sciencedirect.com
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Correlation between the self-rated Apathy Evaluation Scale (minimum
score 18) and Barratt Impulsiveness Scale (minimum score 30) in
73 patients with frontotemporal lobar degeneration syndromes (PSP
25, CBS 17, PPA 17, bvFTD 14; Pearson’s Correlation r = 0.495,
P < 0.001). PSP, progressive supranuclear palsy; CBS, corticobasal
syndrome; PPA, primary progressive aphasia; bvFTD, behavioral
variant of frontotemporal dementia.
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(a) Examples of trajectories of the ‘drift-diffusion’ model. The two
boundaries (a & 0) represent the Go and No-Go decisions. The drift-
rate (velocity) represents the rate of accumulation of evidence. The
diffusion process begins at a starting point between the two
boundaries (z*a) until the accumulated evidence reaches one of the
two boundaries. The predicted movement latency is the sum of the
duration of the diffusion process and the non-decision time (Ter). (b)
Progressive supranuclear palsy (PSP) leads to exaggerated response
bias toward the Go decision boundary, reduced non-decision time
(Ter) and slow accumulation rate. This combination renders PSP
patients both impulsive and slow, in a parsimonious and biologically
plausible decision-model. The pictures in panel (a) and (b) have been
adapted from Ref. [17]. PD, Parkinson’s disease.Neurocognitive mechanisms of apathy and
impulsivity
The examination of behavioral profiles (latencies, accu-
racy, choice preferences) in terms of an accumulation-to-
threshold decision model [17]; or effort allocation models
[18] are key examples of model-based approaches to
study apathy and impulsivity. Such models can parame-
terize effort, fatigue, reward expectations and behavioral
biases, and other latent variables related to apathy and
impulsivity [19,20,21,22]. Differences in the accumula-
tion of ‘evidence’ for effort, or the variation in decision
thresholds according to reward, can be mapped to differ-
ences in brain structure and function [23].
This powerful modeling approach is beginning to eluci-
date the etiology of behavioral changes in FTLD and
Parkinsonian syndromes, such as the similarly deleterious
effect of PSP and Parkinson’s disease (PD) on response
inhibition (Figure 2a). A ‘drift-diffusion’ model describes
the binary-choice between action and inhibition in a Go/
No-Go paradigm, with neuronal ‘accumulators’ integrat-
ing the momentary evidence over-time [20,21,22]. When
this evidence reaches a threshold, the agent is committed
to response, or inhibition of a response. Despite their
profound akinesia, PSP patients, relative to PD patients
and controls, have a markedly increased bias toward
making a Go response. However, they are severely
impaired at accumulating the necessary additional evi-
dence to commit to a response [17]. Through the compu-
tational model of patient behavior, one can see how PSP
patients are simultaneously prone to impulsivity (i.e. biaswww.sciencedirect.com toward a responding, plus noise) and apathy (severe
difficulty to reach threshold) (Figure 2b) [17]. In contrast
to model parameters, the mean reaction-times and errors
did not reveal the cognitive deficits that distinguished
PSP patients from PD patients and controls [17]. Latent
cognitive variables for effort and reward are similarly
derived from saccadic responses [24], and although only
applied thus far to PD, this approach has potential
advantages to study FTLD, where akinesia or rigidity
may interfere with responding over and above the cogni-
tive disorders underlying apathy and impulsivity.
Apathy
The composite nature of goal-directed behavior sup-
ported the theoretical decomposition of apathy into emo-
tional/motivational, cognitive, and behavioral (‘auto-
activation’) subtypes. The first variant relates to blunted
affect, while the cognitive apathy closely resembles the
typical executive deficits observed in FTLD syndromes.Current Opinion in Behavioral Sciences 2018, 22:14–20
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Voxel-based-morphometry analyses revealed distinct white-matter or
grey-matter correlates for patient-related, carer-related and task-
related principal components (after [8]). Patient self-ratings correlated
with white-matter atrophy in cortico-spinal circuits while carer ratings
correlated with diffuse grey-matter deficits in frontostriatal and
frontotemporal regions. Response-inhibition impairments on behavioral
paradigms assessing impulsivity (i.e. stop signal task) correlated with
focal cortical atrophy in prefrontal cortex regions involved in cognitive
control. The color bar represents t-statistics.However, the relationship between apathy and cognition
remains unclear; apathy has been linked to rapid cogni-
tive/functional decline [25], while others have reported
no correlation between apathy and cognition [26]. The
‘auto-activation’ variant reflects a reduced ability to self-
generate motor patterns without external prompting.
This distinction is clinically heuristic but a clear oper-
ationalization of such subtypes is needed to link clinical
observations to modern cognitive neuroscience ontolo-
gies and their neuroanatomical substrates.
Although direct evidence linking brain structural deficits
to different modalities of apathy in FTLD syndromes
remains limited, the motivational apathy has been
hypothesized to arise from deficits from orbital/ventro-
medial prefrontal cortex (PFC)/ventral striatum circuits;
the cognitive apathy from dorsolateral-PFC/caudate net-
works; and the ‘auto-activation’ apathy from premotor/
motor circuits including the supplementary motor area
(SMA) and pre-SMA [27]. Dysfunction of the latter circuit
in FTLD syndromes can cause the failure to self-gener-
ate motor patterns, over and above blunted affect or
cognitive dysfunction, in keeping with evidence for this
circuit in voluntary action selection in health [20,28] and
poor signal-to-noise in motor plans arising from the
medial frontal cortex [29]. This ‘auto-activation’ deficit
can also be formulated as a failure to reach a necessary
activation threshold, by leakage, decay or refractoriness in
the frontoparietal neuronal ensembles that represent
actions [17].
Nevertheless, there is lack of consistency across studies
examining the neuroanatomical substrate of apathy in
FTLD, due to limited numbers of patients, lenient
statistical thresholds, and the inclusion of single diagnos-
tic entities which reduces the generalization of previous
studies. To overcome these limitations, we recommend
multiple modes of assessment of apathy (e.g. behavioral
tests, questionnaires from multiple sources, wearables
technologies) as well as trans-diagnostic approaches that
emphasize the commonality of the manifestation of apa-
thy across the broad clinical spectrum of FTLD diagno-
ses. This enables a data-driven approach to interrogate
the phenomenology and etiology of apathy and impulsiv-
ity [8,30]. For example, Lansdall et al. used a principal
components analysis of multiple questionnaires and lab-
oratory tests, combined with structural magnetic reso-
nance imaging [8,30]. They found a positive correlation
between measures of apathy and impulsivity (Figure 3)
and a dissociation between patient ratings, carer ratings,
and dissociable neural correlates of the different modes of
apathy and impulsivity, depending on the rater (Figure 3)
[8]. Carers’ observations of apathetic changes in behavior
correlated with diffuse atrophy in frontostriatal and fron-
totemporal regions, while patients’ reports related to
deficits in motor networks, suggesting that patients retain
insight in some aspects of their disability. These findingsCurrent Opinion in Behavioral Sciences 2018, 22:14–20 imply that the aspects of FTLD which distress carers and
patients differ: future studies targeting patient-reported
or carer-reported symptoms should choose outcome mea-
sures accordingly.
Impulsivity
Impulsivity is a multi-faceted construct, which reflects
the tendency to act prematurely, with adverse conse-
quences, or with insufficient evidence to make a decision
[31]. Such definitions imply the distinction of impulsivity
into separate neurocognitive systems, with identifiable
neuroanatomical and neurochemical components. For
example, aberrant processing of reward-expectation and
delay-discounting measures (‘risky decision-making’ and
‘waiting impulsivity’), differ from response-inhibition
deficits and cognitive dysregulation (‘stopping’ and
‘reflection’ impulsivity) [31].www.sciencedirect.com
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Left panel. At the macroscopic examination, a patient with
progressive supranuclear palsy (PSP) shows, relative to a healthy
control, paler locus coeruleus (red arrows) reflecting reduced
intracellular neuromelanin. Right panel. There is also evidence that
tau pathology (red arrows) is present in the locus coeruleus in PSP.The neural determinants of impulsivity in FTLD syn-
dromes include: subcortical FTLD-related pathological
changes within striatal, thalamic, and sub-thalamic neu-
rons which affect reward processing and dis-inhibition of
thalamo-cortical loops, with consequent biases toward
contextually inappropriate actions [21,22,32]; and neo-
cortical pathology, especially in PFC networks, which
impair decision-making and action selection processes
[33]. Lesions at different points across the functional
gradients of interlocking PFC-striato-thalamo-cortical cir-
cuits affect different modes of impulsivity [31].
For example, degeneration of ‘limbic’ ventral PFC-striatal
circuits leads to risky decision-making and delay intoler-
ance while neurodegeneration in dorsal ‘motor’ and
‘cognitive’ circuits impairs the ability to refrain from or
cancel inappropriate actions. These effects span animal
models of impulsive disorders [34], neuroimaging data from
individuals with impulsive neurodevelopmental disorders
[35] and adult neuropsychiatric patients (e.g. obsessive-
compulsive disorders and PD) [21,22,36]. The prevalence
of impulsivity in these diverse conditions highlights  the
value of translational and trans-diagnostic  approaches to
elucidate the neural underpinnings of impulsivity [8,30].
In the study by Lansdall et al. [12], the response-inhibition
deficits observed during laboratory-based behavioral para-
digms (e.g. the stop-signal task of response cancelation)
correlated with focal atrophy in the inferior frontal gyrus
and pre-SMA. These are two critical ‘hubs’ in cognitive and
motor control, and the target of therapeutic strategies which
we consider in the next section [7,13–15].
Neuropharmacology of apathy and impulsivity
The emotional/motivational contributors to apathy have
been linked to the dopaminergic reward system [37], but
the pharmacology of ‘auto-activation’ deficits is unclear. A
link between dopamine, reward, and motivation is well
established in health and PD [38], but the motor and
affective components of incentive motivation are disso-
ciated and the principal determinants of apathy in PD
may be distinct from apathy in FTLD [39]. In clinical
practice, apathy in FTLD syndromes is frequently unre-
sponsive to anti-parkinsonian dopaminergic medications,
although dopamine deficiency is common in FTLD, not
only the overtly parkinsonian disorders like PSP, but also
the bvFTD. For example, half cases of FTD-linked
C9orf72 mutation develop parkinsonism, and this common
mutation is associated with striatal dopamine deficiency.
The extent to which this causes apathy and impulsivity, as
opposed to atrophy on frontostriatal circuits, remains
unclear. It is possible that dopamine deficiency in some
circuits and the relative preservation in other circuits is
accompanied by dopaminergic ‘overdose’, as in PD [40],
contributing to impulsivity in FTLD syndromes.
We propose that dysfunction of the noradrenergic system
may play a key role in the pathogenesis of apathy,www.sciencedirect.com especially in FTLD syndromes [16]. There are early
pathological changes in the locus coeruleus (LC) in post
mortem tissue from FTLD patients (Figure 4) [33]. The
LC is the principal source of noradrenaline in the fore-
brain, which regulates the neuronal signal-to-noise ratio
in the neocortex, gating information processing and mod-
ulating arousal [41]. It is possible that the dopaminergic
and noradrenergic systems influence different compo-
nents of goal-directed behavior (e.g. motivation and
energization) [41,42], but such a dichotomy is over-
simplistic, and there is counter evidence for strong inter-
actions between the dopaminergic and noradrenergic
neurotransmission [42].
Impulsivity in FTLD syndromes may reflect dysfunc-
tions in multiple monoaminergic systems, including sero-
tonin, noradrenaline, and dopamine [43]. The reduction
of serotonin in FTLD reported by Bowen and Proctor
through post mortem studies, led Hughes and colleagues
to test whether the serotonin reuptake inhibitor citalo-
pram could restore the functional systems for response
inhibition [44]. As predicted, bvFTD patients had a
functional deficit in the PFC when required to inhibit
actions, but this deficit was restored by citalopram. Clini-
cal trials are necessary before this approach could be
introduced therapeutically, but the study indicates the
value of a translational approach, across species and across
disorders [13,44].
Noradrenaline is necessary to effectively cancel ongoing
behaviors when the context changes, in animal models
and healthy humans [45]. There is growing evidence for
the role of noradrenaline deficiency in impulsivity in
FTLD syndromes [14,15,46]. The early and severe
pathology in the LC in FTLD [33,47] suggests that
restoring noradrenergic neurotransmission might be aCurrent Opinion in Behavioral Sciences 2018, 22:14–20
18 Apathy and motivation
Figure 5
(a) (b)
‘Emotional’ apathy
‘Risky-choice’ impulsivity
‘Auto-activation’ apathy
‘Stopping’ impulsivity
‘Cognitive’ apathy
‘Reflection’ impulsivity
– Motivation
– Reward discounting
– Adaptive function/Energization
– Action cancellation
– Action restrain
DA
NA
5-HT
Neuroanatomy Neurochemistry
Current Opinion in Behavioral Sciences 
Shared neuroanatomical and neurochemical mechanisms underlying apathy and impulsivity in frontotemporal lobar degeneration syndromes. (a)
Different modes of apathy and impulsivity are mediated by relatively segregated frontostriatal circuits (the frontal and striatal areas sharing the
same coloring show direct anatomical and functional connectivity) [48,49]. (b) The dopaminergic, noradrenergic, and serotoninergic systems are
involved in regulating different aspects of apathy and impulsivity. Abbreviations: dACC, dorsal anterior cingulate cortex; sgACC, subgenual anterior
cingulate cortex; vmPFC, ventromedial prefrontal cortex; mOFC, medial orbitofrontal cortex; VS, ventral striatum; SMA, supplementary motor area;
dmPFC, dorsomedial prefrontal cortex; aPFC, anterior prefrontal cortex; Put, putamen; DLPFC, dorsolateral prefrontal cortex; VLPFC, ventrolateral
prefrontal cortex; lOFC, lateral orbitofrontal cortex; Caud, caudate; VTA, ventral tegmental area; SN, substantia nigra; LC, locus coeruleus; RN,
raphe nuclei. The pictures in panel (a) have been adapted from Ref. [50].therapeutic target for impulsivity. One candidate is the
noradrenergic reuptake inhibitor atomoxetine, which
restores activity and connectivity in inhibitory control
networks in another disorder with noradrenergic defi-
ciency, PD [14]. Together, these results suggest that
targeting noradrenergic transmission may be a useful
treatment for apathy and impulsivity in FTLD
syndromes.
Concluding remarks
We propose that apathy and impulsivity are not opponent
manifestations of a unidimensional behavioral spectrum,
but instead are multi-dimensional behavioral constructs
resulting from common neuroanatomical and neurochem-
ical deficits (Figure 5). To improve effective therapeutic
strategies in FTLD, we recommend targeting apathy and
impulsivity jointly, ensuring that chosen assessment tools
capture each of their principal dimensions. There is a
pressing need to develop improved assessment tools for
apathy and impulsivity, to empower clinical trials in terms
of stratification and outcome markers. These areCurrent Opinion in Behavioral Sciences 2018, 22:14–20 especially relevant to trans-diagnostic therapies, which
would maximize the impact of effective new treatments
to a larger population of patients and carers alike.
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